Intrasense and Guerbet announce CE certification of Myrian 2.12, enhanced with Guerbet's prostate AI

Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions and developer of Myrian®, and Guerbet (FR0000032526 GBT), world leader in medical imaging, are proud to announce that the Myrian® 2.12 platform has obtained CE certification under MDR1, integrating prostate AI developed by Guerbet, the Veolity® LungCAD AI developed by MeVis Medical Solutions AG and the Icobrain™ AI developed by Icometrix. This market launch is a major step in the two companies' joint development plan and the realization of their growth ambitions.


A strategic innovation step

Myrian® successfully obtained CE certification for its new version 2.12 on April 5, 2024, enabling it to be marketed in Europe.

The integration of AI algorithms within Myrian®, a platform renowned for its ease of use and wide range of functions, offers radiologists easier interpretation of medical imaging examinations thanks to cutting-edge technologies directly available in their workflow.

The certification of this new version of the Myrian® platform enables Intrasense to accelerate its expansion strategy in Europe, taking advantage of the collaboration with Guerbet to increase its international visibility and explore new markets.

«The certification of our Myrian® 2.12 solution represents a major milestone in our innovation strategy. This validation marks our ongoing commitment to technological excellence and is also an opportunity to accelerate our growth. The new AI algorithms, developed in particular by our partner Guerbet, will enable us to reinforce the added value of our software solutions and maximize the relevance of our offering in the marketplace » says Nicolas Reymond, CEO of Intrasense.

Guerbet launches DUOnco™ AI brand

Guerbet announces the launch of its DUOnco™ commercial brand, which will bring together all the Group's artificial intelligence algorithms. DUOnco™ brand algorithms will be integrated into Intrasense's product portfolio and may, subject to regulatory certification, also be marketed in stand-alone mode to partners by Intrasense and Guerbet.

In addition to AI for prostate cancer, Guerbet is also working on several algorithms dedicated to the detection of cancerous lesions in the liver, pancreas and bone.


Integration of Guerbet’s AI dedicated to prostate cancer

The integration of Guerbet's prostate AI within Intrasense solutions marks a major milestone in the industrial and commercial collaboration between the two players.

François Nicolas, Senior Vice-Président R&D and Innovation and Chief Digital Officer of Group Guerbet underlines the importance of this breakthrough: « Our prostate AI is the first algorithm developed by our teams to benefit from the full synergy resulting from our merger with Intrasense. The combination of the medical relevance of our AI and the ergonomics of Myrian® enables us to market a unique solution that offers radiologists diagnostic assistance and efficiency gains for this very common cancer. »

With 1.4 million new cases worldwide each year, prostate cancer is the second most common cancer among men2. MRI plays an essential role in its detection and follow- up, but its interpretation remains complex for radiologists. Guerbet, winner of the PI-CAI3 international challenge on prostate cancer detection, has put all its medical and algorithmic expertise to work in support of radiologists.

Perfectly integrated within tools dedicated to clinical routine, AI facilitates diagnosis and therapeutic decision-making. Prostate AI automatically segments the prostate and provides its volume, simplifying the calculation of PSA (prostate- specific antigen) density. Thanks to a probability map, AI also highlights suspicious areas to help radiologists detect lesions that may correspond to clinically significant cancer.

This collaboration enables Intrasense to enrich its solutions with cutting-edge clinical tools, providing healthcare professionals with precious tools to enhance diagnostic performance in prostate MRI analysis.


Expanding the product portfolio

Myrian 2.12 integrates a second new feature in oncology imaging: an AI for detecting lung lesions. Developed by MeVis Medical Solutions AG, the AI Veolity® LungCAD is one of the most powerful lung solutions on the market. Thanks to the capabilities of the Myrian® platform, Veolity® LungCAD is natively integrated into the application dedicated to lung nodules, enabling clinicians to benefit from advanced technology in their daily practice.

Icobrain AI, developed by Icometrix, also enriches the Intrasense product portfolio, enabling precise quantification of brain structures, opening up new perspectives in diagnostic neurology.

The ergonomic design of this new version of Myrian® have been revisited to simplify the interpretation of imaging examinations and enhance the user experience. These initiatives reflect Intrasense's commitment to continuous improvement of its historic platform, guaranteeing smealess use for clinicians.




About Intrasense

French expert in medical imaging since 2004, Intrasense develops and markets software platforms in 40 countries, facilitating and securing diagnosis, decision-making and therapeutic follow-up.

Myrian®, an advanced visualization solution for radiology, provides 1,200 healthcare establishments with clinical applications to help interpret all types of images. Since 2021, Intrasense has been developing Liflow®, a new platform dedicated to oncology, multidisciplinary and collaborative, to optimize patient care and follow-up. A Guerbet Group subsidiary since June 2023, Intrasense continues to enhance its solutions by integrating artificial intelligence algorithms in medical imaging. Its teams work closely with healthcare professionals to help save lives.

Learn more at


About Guerbet

At Guerbet, we build lasting relationships to help people live better. This is our raison d'être. We are a global leader in medical imaging, offering a comprehensive range of pharmaceutical products, medical devices and digital and AI solutions for diagnostic and interventional imaging. A pioneer for 95 years in the field of contrast media, with more than 2,830 employees worldwide, we are constantly innovating and devote 10% of our sales to Research & Development in four centers in France, Israel and the United States. Guerbet (GBT) is listed in compartment B of Euronext Paris and achieved a turnover of €786 million in 2023.

For further information, please visit


Intrasense Salomé Sylvestre
Communications officer

Phone: +334 67 13 01 30

NewCap Thomas Grojean
Financial Communication and investor relations

Phone: +331 44 71 20 40

Guerbet Christine Allard
Director of Public Affairs and Communications

Phone: +33 6 30 11 57 82


1 European Union Medical Devices Regulation 2017/745

2 GLOBOCAN 2020 study